Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
Cell Therapies & Delivery
Carisma Therapeutics is developing of CAR macrophages for immunotherapy. Their technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular ...
Cellular therapy, diagnostics
Mogrify has developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) ...
Celularity is a biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta. These materials have the ability to augment our immunity and longevity by ...
Engineers B cells through gene therapy to produce proteins that combat disease.
Developing industrial scale genome editing for therapeutics and therefore making gene therapies universally accessible.
Universal donor cell therapy
Embryonic cell-based therapies for bone and cartilage injuries and disease.
Developing personalized adoptive cell therapies with neoantigen-targeted T Cells against cancer.
Cell Therapy Development Support
Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Over two decades, Sangamo's scientists developed the most advanced, flexible and ...
Developing cell therapies.
Sigilon Therapeutics is developing improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the ...
TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies.